JEAN DAVIS: Open Payments
NPI 1801294756 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,157 in 56 payments from 13 companies in 2025. Trend: 2023 $1,714 · 2024 $3,051 · 2025 $1,157
Food & beverage: $1,157
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $297 |
| Janssen Biotech, Inc. | 9 | $182 |
| Gilead Sciences, Inc. | 7 | $137 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $94 |
| Madrigal Pharmaceuticals | 4 | $91 |
| Organon LLC | 5 | $91 |
| Intercept Pharmaceuticals, Inc. | 4 | $77 |
| Ipsen Biopharmaceuticals, Inc | 2 | $47 |
| Napo Pharmaceuticals Inc | 2 | $39 |
| Mirum Pharmaceuticals, Inc. | 1 | $34 |
Products named: TREMFYA, RINVOQ, SKYRIZI, XIFAXAN, REZDIFFRA, HADLIMA, OCALIVA, MAVYRET.
Industry payments across TX — which companies pay providers there.
